Fintel reports that OBF Investments has filed a 13G/A form with the SEC disclosing ownership of 0.85MM shares of iSpecimen Inc. (ISPC). This represents 9.5% of the company.
In their previous filing dated February 14, 2022 they reported 0.84MM shares and 9.70% of the company, an increase in shares of 1.02% and a decrease in total ownership of 0.20% (calculated as current - previous percent ownership).
Analyst Price Forecast Suggests 322.39% Upside
As of February 13, 2023, the average one-year price target for iSpecimen is $6.88. The forecasts range from a low of $4.29 to a high of $11.55. The average price target represents an increase of 322.39% from its latest reported closing price of $1.63.
The projected annual revenue for iSpecimen is $12MM, an increase of 22.80%. The projected annual EPS is -$1.30.
What is the Fund Sentiment?
There are 26 funds or institutions reporting positions in iSpecimen. This is a decrease of 2 owner(s) or 7.14% in the last quarter. Average portfolio weight of all funds dedicated to ISPC is 0.00%, a decrease of 2.37%. Total shares owned by institutions increased in the last three months by 29.58% to 532K shares.
What are large shareholders doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 127K shares representing 1.42% ownership of the company. In it's prior filing, the firm reported owning 25K shares, representing an increase of 80.64%. The firm increased its portfolio allocation in ISPC by 307.51% over the last quarter.
Bleichroeder holds 66K shares representing 0.74% ownership of the company. No change in the last quarter.
Grimes holds 66K shares representing 0.74% ownership of the company. In it's prior filing, the firm reported owning 66K shares, representing a decrease of 0.00%. The firm decreased its portfolio allocation in ISPC by 25.94% over the last quarter.
Teton Advisors holds 40K shares representing 0.45% ownership of the company. No change in the last quarter.
WMMAX - Teton Westwood Mighty Mites Fund holds 40K shares representing 0.45% ownership of the company.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
